BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32604720)

  • 1. MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.
    Motti ML; Minopoli M; Di Carluccio G; Ascierto PA; Carriero MV
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
    Haugh AM; Salama AKS; Johnson DB
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
    Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
    JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.
    Jiang X; Zhou J; Giobbie-Hurder A; Wargo J; Hodi FS
    Clin Cancer Res; 2013 Feb; 19(3):598-609. PubMed ID: 23095323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
    Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
    Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
    Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
    J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
    Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
    Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?
    Haist M; Stege H; Kuske M; Bauer J; Klumpp A; Grabbe S; Bros M
    Cancer Metastasis Rev; 2023 Jun; 42(2):481-505. PubMed ID: 37022618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.
    Ojha R; Leli NM; Onorati A; Piao S; Verginadis II; Tameire F; Rebecca VW; Chude CI; Murugan S; Fennelly C; Noguera-Ortega E; Chu CT; Liu S; Xu X; Krepler C; Xiao M; Xu W; Wei Z; Frederick DT; Boland G; Mitchell TC; Karakousis GC; Schuchter LM; Flaherty KT; Zhang G; Herlyn M; Koumenis C; Amaravadi RK
    Cancer Discov; 2019 Mar; 9(3):396-415. PubMed ID: 30563872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF inhibitors and their immunological effects in malignant melanoma.
    Adams R; Coumbe JEM; Coumbe BGT; Thomas J; Willsmore Z; Dimitrievska M; Yasuzawa-Parker M; Hoyle M; Ingar S; Geh JLC; MacKenzie Ross AD; Healy C; Papa S; Lacy KE; Karagiannis SN
    Expert Rev Clin Immunol; 2022 Apr; 18(4):347-362. PubMed ID: 35195495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
    Welsh SJ; Rizos H; Scolyer RA; Long GV
    Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade.
    Shin MH; Kim J; Lim SA; Kim J; Lee KM
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32260561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial Approaches to the Treatment of Advanced Melanoma.
    Munhoz RR; Postow MA
    Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
    Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
    J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
    Yeon M; Kim Y; Jung HS; Jeoung D
    Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
    Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
    Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
    Paulitschke V; Eichhoff O; Cheng PF; Levesque MP; Höller C
    Curr Opin Oncol; 2016 Mar; 28(2):172-9. PubMed ID: 26742019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.